Macrophage origin, phenotypic diversity, and modulatory signaling pathways in the atherosclerotic plaque microenvironment

Na Liu, Baihui Zhang, Yanlong Sun, Weiguo Song, Shoudong Guo

Institute of Lipid Metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, Shandong, China.

Correspondence to: Dr. Shoudong Guo, Institute of Lipid Metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, Shandong, China. E-mail: SD-GUO@hotmail.com; Dr. Weiguo Song, Institute of Lipid Metabolism and Atherosclerosis, Innovative Drug Research Centre, School of Pharmacy, Weifang Medical University, Weifang 261053, Shandong, China. E-mail: williamsong@doyepharma.com

How to cite this article: Liu N, Zhang B, Sun Y, Song W, Guo S. Macrophage origin, phenotypic diversity, and modulatory signaling pathways in the atherosclerotic plaque microenvironment. Vessel Plus 2021;5:43. https://dx.doi.org/10.20517/2574-1209.2021.25

Received: 9 Feb 2021 First Decision: 17 Mar 2021 Revised: 23 Mar 2021 Accepted: 25 May 2021 First online: 1 Jul 2021

Academic Editors: Rupinder Kaur Kanwar, Alexander D. Verin Copy Editor: Yue-Yue Zhang Production Editor: Yue-Yue Zhang

Abstract

Atherosclerosis is the main pathological basis of most cardiovascular diseases and the leading health threat in the world. Of note, lipid-lowering therapy cannot completely retard atherosclerosis progression, even in patients treated with combined statins and PCSK9 inhibitors. This failure further impels researchers to explore other underlying therapeutic strategies except for lipid-lowering. Monocytes and macrophages are the major immune cell groups in atherosclerotic plaques. They play important roles in all stages of atherosclerosis, including the occurrence, advance, and regression. It is interesting that macrophages are demonstrated to have plastic and heterogenous characteristics within the dynamic atherosclerotic plaque microenvironment. Furthermore, the phenotype of macrophages can switch upon different microenvironmental stimulus. Therefore, macrophages have become a potential therapeutic target for anti-atherosclerosis treatment. This article reviews the phenotypic diversity of macrophages and their roles in dynamic atherosclerotic plaque microenvironment, especially the related signaling pathways involved in macrophage polarization and compounds exhibiting therapeutic effects.

Keywords: Atherosclerosis, microenvironment, signaling, polarization, treatment
INTRODUCTION

Atherosclerosis is a progressive inflammatory disease that mainly affects large- and medium-sized arteries\(^1\)\(^-\)\(^3\). This disease is characterized by the formation of atherosclerotic plaques, which are composed of lipids, necrotic nuclei, calcified areas, inflammatory cells, endothelial cells, immune cells, and foam cells\(^1\)\(^-\)\(^3\). Monocytes-derived macrophages are the most abundant type of immune cells in atherosclerotic plaques and play a key role in the progression and regression of atherosclerosis\(^4\)\(^-\)\(^6\).

Atherosclerosis is initiated by deposition of cholesterol-rich lipoproteins, such as oxidized low-density lipoproteins (ox-LDL), in the arterial wall\(^6\)\(^-\)\(^7\). This pathological alteration promotes the production of cytokines and chemokines that can recruit monocytes from circulation. In the following, monocytes can differentiate into macrophages upon the stimuli of the local atherosclerotic plaque microenvironment\(^6\)\(^-\)\(^7\). Mature macrophages express a variety of scavenger receptors, such as scavenger receptor A (SR-A) and cluster of differentiation (CD) 36, which are responsible for scavenging modified lipoproteins within the plaque\(^1\)\(^-\)\(^3\),\(^8\)\(^-\)\(^10\). Accumulation of neutral lipids in macrophages promotes the formation of foam cells, which is considered as a protective mechanism for clearance of deposited lipids from the arterial wall\(^1\)\(^-\)\(^3\),\(^10\)\(^-\)\(^12\). However, excessive accumulation of foam cells in the arterial wall leads to the formation of advanced atherosclerotic plaques\(^1\)\(^-\)\(^12\). Of note, the total number of macrophages is associated with the progress and severity of the plaque, and symptomatic plaques have more macrophages than asymptomatic plaques\(^1\)\(^-\)\(^12\). These atherosclerotic plaques cause narrowing of the arteries, which limits or stops blood flow to the tissue, inducing various cardiovascular events\(^1\)\(^-\)\(^12\).

Atherosclerotic plaque microenvironmental stimuli influence the phenotypes and functions of macrophages, which in turn play key roles in atherosclerotic plaque progression and regression\(^6\),\(^14\)\(^-\)\(^15\). Macrophages are simply divided into classically activated (M1) and alternatively activated (M2) subtypes, which have been extensively studied since the end of the last century\(^16\)\(^-\)\(^18\). In terms of numbers, the pro-inflammatory M1 macrophages are enriched in progressing plaques, while the anti-inflammatory M2 macrophages are dominant in regressing plaques\(^19\)\(^-\)\(^21\). Moreover, accumulating evidence suggests that the phenotypic shift of plaque macrophages from an M1 phenotype to an M2 phenotype appears to play important roles in maintaining plaque stability and promoting atherosclerosis regression\(^16\)\(^-\)\(^18\). Over the past decade, the original classification of macrophages (M1 and M2) has been challenged due to the gradual discovery and identification of other macrophage subpopulations. These subpopulations of macrophages possess distinctive functional phenotypes in response to specific signals of the atherosclerotic plaque microenvironment\(^1\)\(^-\)\(^3\),\(^16\)\(^-\)\(^21\).

Presently, the therapeutic strategies for atherosclerosis are mainly aimed at lipid-lowering. However, clinical data demonstrate that these strategies are not powerful enough to inhibit the progression of atherosclerosis and especially to promote its regression\(^24\)\(^-\)\(^26\). As mentioned above, the macrophages with plasticity in the dynamic atherosclerotic plaque microenvironment may be a potential therapeutic target. In this review, we summarize the recent advances in macrophage heterogeneity, macrophage metabolism, macrophage polarization, and potential modulatory signaling pathways in the context of atherosclerosis.

MONOCYTES RECRUITMENT AND DIFFERENTIATION INTO MACROPHAGES

Monocytes are derived from hematopoietic stem cells in the bone marrow and play important roles in the defense system. Monocytes exude blood vessels and enter tissues and organs, where they further differentiate into macrophages and become the most phagocytic cells in the body\(^24\). Monocytes and macrophages are involved in the progression of cardiovascular disease, and they are associated with the development of atherosclerotic plaques\(^27\).
In mice blood, monocytes, especially the classical Ly6C+ cells, are generated by bone marrow. The migration of these monocytes from bone marrow requires C-C motif chemokine receptor 2 (CCR2), which is expressed only in Ly6C+ cells\(^{28}\). Furthermore, mitogen-activated protein kinase kinase kinase 8 (MAP3K8) deletion affects the number of monocytes and the production of inflammatory cytokines in the atherosclerotic lesions via decreasing CCR2 mRNA and protein levels, suggesting the important role of MAP3K8 in this process\(^{28}\). In human blood, monocytes are generated by bone marrow and spleen, and they can be classified into at least three types: classical monocytes (CD14hiCD16- cells), intermediate monocytes (CD14++CD16+ monocytes), and non-classical monocytes (CD14lowCD16++ cells)\(^{11,29,30}\). Classical mononuclear cells account for the majority of these cells. Recently, multicolor flow cytometry and mass cytometry analysis have further improved our knowledge about monocyte subtypes\(^{31,32}\). For instance, Hamers et al.\(^{33}\) recently described eight human monocyte subtypes distinguished by 34 unique surface markers. Furthermore, the expansion of Slan+CXCR6+ nonclassical monocytes in individuals is associated with coronary artery disease. Accumulating studies have demonstrated the phenotypic diversity of monocytes and highlights the unique migratory and efferocytotic capacity of each subtype, which may ultimately influence the development tendency of atherosclerosis\(^{34,35}\).

In the case of atherosclerosis, when monocytes adsorb or invade the endothelium, the autoregulatory and anti-thrombotic effects of endothelial cells are weakened, thereby promoting the occurrence of atherosclerosis\(^{4,36}\). Mononuclear cells have obvious deformable characteristic and are responsible for clearing injured, senescent, dead cells, and cell debris. Upon atherosclerosis, the recruited monocytes are predominantly pro-inflammatory cells that have a high invasive capacity to enter tissues and become macrophages\(^{35,36}\). The recruitment of monocytes is critical to the formation of atherosclerosis plaques. It has been demonstrated that the number of circulating monocytes is positively related to the number of macrophages in the atherosclerotic plaques\(^{43}\). Multiple factors, such as hypercholesterolemia, hyperglycemia, and life habits (e.g., smoking), can influence monocyte recruitment.

Hypercholesterolemia is an important factor contributing to atherosclerosis\(^{24,41}\). Accumulation of lipids, especially cholesterol, in the arterial wall is the main feature of atherosclerosis. In response to lipid accumulation, monocytes and macrophages exhibit different gene expression and lipid metabolism\(^{42}\). For example, high lipoprotein X in hypercholesterolemia drives monocytes changes, such as upregulation of SR-A and CD36, which enhance uptake of modified low-density lipoprotein (LDL), such as ox-LDL, leading to the formation of foam cells\(^{33-45}\). Of note, ox-LDL induces monocyte activation through abnormal regulation of the dual specificity phosphatase-1 and p38 mitogen-activated protein kinase (MAPK) signaling axis\(^{46}\). Accumulation of monocytes under the endothelium, leading to plaque development, and the following activation of smooth muscle cells contribute the majority of foam cells in mice atherosclerotic plaques\(^{47,48}\).

The production of reactive oxygen species (ROS) induced by obesity and hyperglycemia may contribute to the induction of M1-like pro-inflammatory macrophages by activating the related signaling pathways\(^{49}\). Significantly, diabetes mellitus is characterized by an increase in inflammatory monocytes/macrophages as well as high levels of tumor necrosis factor (TNF) α, interleukin (IL)-1β, and IL-6\(^{50-52}\). These alterations, such as activated Ly6Chigh monocytes, further contribute to hyperglycemia and insulin resistance\(^{53,54}\). Of note, high-density lipoprotein reduces proliferation of bone marrow progenitor cells via inhibiting cholesterol accumulation, and it decreases the production of monocytes and their general recruitment to the inflammatory sites, thus alleviating atherosclerosis\(^{54}\).

Smoking influences all stages of atherosclerotic plaque formation\(^{55,56}\). Cigarette smoking is associated with vascular endothelial dysfunction, increased expression of monocyte tissue factor, and oxidative stress due to
the increased ROS production and decreased antioxidant defense systems\(^{[77,56]}\). These changes have an important effect on monocyte recruitment. Cigarette smoke condensate can induce the differentiation of THP-1 monocytes into macrophages and significantly increase the levels of CD14 and CD36. In addition, smoking-induced expression of miR-124-3p in circulation can induce monocyte transformation into foam cells, contributing to the formation of atherosclerotic plaques\(^{[50]}\). Furthermore, cigarette smoke condensate may activate the NLRP3 inflammasome and production of high levels of IL-1\(\beta\) and IL-18 possibly via the myeloid differentiation primary response 88/nuclear factor kappa-B (NF-kB) pathway\(^{[56,60]}\). Notably, the activated NLRP3 inflammasome may enhance the levels of scavenger receptors, cholesterol esterification, and matrix metalloproteins, thereby promoting atherosclerosis progression\(^{[61]}\).

**MACROPHAGE PHENOTYPIC DIVERSITY AND FUNCTIONS**

Accumulation of macrophages within the arterial wall is a characteristic feature of atherosclerosis. Previously, macrophages are classified into two main types, designated as pro-inflammatory M1 and anti-inflammatory M2 macrophages\(^{[62-64]}\). In fact, atherosclerosis macrophages are influenced by multiple plaque microenvironmental stimuli, such as oxidized lipids, cytokines, and senescent erythrocytes\(^{[21-23]}\). Growing evidence demonstrates that atherosclerotic plaque microenvironment can induce distinct subpopulations of macrophages, as summarized in Table 1.

Classically activated M1 macrophages are mainly induced by microbial products such as cytokines TNF and interferon (IFN) \(\gamma\) or lipopolysaccharide (LPS)\(^{[63,64]}\). These macrophages produce high levels of IL-12 and IL-23, low levels of IL-10, and secrete the pro-inflammatory cytokines TNF, IL-6, and IL-1\(\beta\)\(^{[52,65]}\). Functionally, M1 macrophages are responsible for the removal of pathogens during infection by activating the NADPH oxidase system and subsequent production of ROS\(^{[66]}\). However, these reactive oxygen and nitrogen species generated by M1 macrophages may worsen oxidative stress in the atherosclerotic plaques\(^{[29]}\). With the development of inflammation, IL-10, IL-4, or IL-13 alternatively activates M2 phenotype macrophages that bearing anti-inflammatory functions. These cells express IL-10, transforming growth factor (TGF) \(\beta\) and arginase 1 (ARG1)\(^{[41]}\). M2 macrophages can be further divided into M2a, M2b, M2c, and M2d subtypes; each subtype is induced by different cytokines\(^{[47]}\). Of note, M2a, M2b, and M2c subtypes play key roles in anti-inflammation and immune regulation\(^{[69]}\). M2a macrophages are activated by IL-4 and IL-13, and they produce IL-10 as well as low levels of IL-12. These cells express high levels of mannose receptor (CD206), fibrotic factors, and TGF-\(\beta\), which participate in tissue repair and wound healing\(^{[49-72]}\). Furthermore, these cells display high phagocytic capacity and low cholesterol efflux capacity due to the decreased expression of ATP-binding cassette (ABC) transporters. Immune complexes or toll-like receptor (TLR) activation in combination with IL-1\(\beta\) or LPS induces M2b macrophages, which express high levels of anti-inflammatory cytokine IL-10\(^{[73]}\). M2c macrophages are activated by glucocorticoid, IL-10, or TGF-\(\beta\) and produce anti-inflammatory factors\(^{[74,75]}\). M2b and M2c macrophages express high levels of proto-oncogene tyrosine protein kinase MER, a major apoptotic cell receptor, contributing to their phagocytic and immunomodulatory capacity\(^{[76,77,78,79]}\). M2d macrophages are stimulated by IL-6 and adenosine A(2A) receptor activation (e.g., agonists), characterized by the increased expression of IL-10 and vascular endothelial growth factor and reduced expression of TNF and IL-12\(^{[77,78]}\). These cells play a key role in angiogenesis\(^{[78,79]}\). Additionally, macrophage subpopulations have also been classified based on hemostatic roles of macrophages, including host defense macrophages (M1), wound healing macrophages (M2a), and immune regulatory macrophages (M2b/c)\(^{[73]}\). However, recent studies demonstrated that M2 macrophages are not always protective\(^{[80]}\).

In recent years, oxidized phospholipids have been reported to induce Mox macrophages via the transcription factor nuclear erythroid-2 related factor\(^{[46]}\). Mox macrophages exhibit a morphological
### Table 1. Macrophage phenotype, markers, secreta, and functions

| Phenotype | Stimuli | Human markers | Mice markers | Cytokines, chemokines, and other secreted mediators | Functions |
|-----------|---------|---------------|--------------|-----------------------------------------------------|-----------|
| **M1**    | IFN-γ, LPS, GM-CSF, TNF-α | IL1β, TNF, IL6, IL12, IL23, CXCL9, CXCL10, CXCL11, SOCS1, MARCO, TLRs, iNOS | IL1β, TNF, IL6, IL12, IL23, CXCL9, CXCL10, CXCL11, Arg II, TLRs, iNOS | TNF-α, IL (1β, 6, 12, 23), CCL (2, 3, 4, 5, 8, 9, 10, 11), MMDP (1, 3, 9), iNOS, ROS | Pro-inflammation, host defense, tumor resistance, bacterial killing |
| **M2a**   | IL-4, IL-13 | CD68, CD163, MHC II, MR, CD200R, IL-1Ra, CCL18, Dectin-1, IL-1R II, DC-SIGN | Arg-1, resistin-like α, Ym1, Ym2, MMGL, stabilin1, CD63, Dectin-1, Chili3, FIZZ1 | IL10, TGF-β, IL-1Ra, CCL17, CCL18, CCL22, CCL24 | Anti-inflammatory, tissue repair, wound healing, allergy, parasite killing |
| **M2b**   | Immune complexes, TLR Ligands, IL-1β | CCL1, IL-10 high/IL-12 low, TNF-α, CD86, IL-6, MHC II, MR | CCL1, IL-10 high/IL-12 low, TNF-α, CD86, IL-6, MHC II, MR, LIGHT | TNF-α, IL-1β, IL-6, IL-10, CCL1 | Immunoregulation, phagocytosis, iron-storage, high oxidative capacity |
| **M2c**   | IL-10, TGF-β, glucocorticoids | CXCL13, MR, CD163, IL-10, TGF-β, MerTK, TLRs, Tie-2 | CXCL13, MR, CD163, IL-10, TGF-β, MerTK, Arg-1 | IL-10, TGF-β, CCL16, CCL18, CXCL13 PTX3 | Immunoregulation, phagocytosis, matrix deposition, tissue remodeling, effector cytokine capacity |
| **M2d**   | LPS+A2R ligands, IL-6 | VEGF, IL-10, TGF-β | VEGF, IL-10, TGF-β, iNOS | IL-10, VEGF, iNOS | Immunosuppression, phagocytosis, tissue remodeling, Pro-tumoral, proangiogenic capacity |
| **Mox**   | Oxidized phospholipids | MR, MMP7, S100A8 | MR, MMP7, S100A8 | MMP12, IL-6, TNF-α, MMP-7 | Proinflammatory, cytotoxicity, monocyte recruitment |
| **Mhem**  | Heme | HMOX-1, Nrf2, Srxn1, Txnrd1 | HMOX-1, Nrf2, Srxn1, Txnrd1 | IL-10, IL-1β, COX-2 | Proatherogenic, proinflammatory, antioxidative |
| **M(Hb)** | Hemoglobin/haptoglobin complexes | CD163, ATF-1, MCH II | CD163, ATF-1, MCH II | IL-10, HMOX-1, LXRβ | Antioxidant erythropagocytosis, atheroprotective |

ABC: ATP binding cassette transporter; Arg1: arginase 1; A2R: A2adenosine receptor; ATF-1: cyclic AMP-dependent transcription factor-1; CCL: chemokine (C-C motif) ligand; CD: cluster of differentiation; Chil3: chitinase-like 3; COX: cyclooxygenase; CXCL: chemokine (C-X-C motif) ligand; DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; FIZZ1: found in inflammatory zone 1; GM-CSF: granulocyte-monocyte colony stimulating factor; HMOX: heme oxygenase; IFN: interferon; IL: interleukin; iNOS: inducible nitric oxide synthase; LIGHT: homologous to lymphotoxin, inducible expression, competes with herpes simplex virus (HSV) glycoprotein D for binding to HSV entry mediator, a receptor expressed on T lymphocytes; LPS: lipopolysaccharide; LXR: liver X receptor; MARCO: macrophage receptor with collagenous structure; MerTK: Mer receptor tyrosine kinase; MMGL: C-type lectin domain family 10 member A (also known as MGL-1); MMP: matrix metalloproteases; MR: mannose receptor (CD206); MCH: major histocompatibility complex; PTX3: pentraxin 3; ROS: reactive oxygen species; SOCS1: suppressor of cytokine signaling 1; Srx: Sulforedoxin-1; TGF-β: transforming growth factor β; TLRs: toll-like receptors; TNF: tumor necrosis factor; Txnrd1: Thioredoxin reductase 1; VEGF: vascular endothelium growth factor.

Structure and biological functions that differ from M1 and M2 macrophages. In hypercholesterolemia mice, Mox macrophages account for about 30% of the total macrophages. These cells express pro-inflammatory markers, such as IL-1β and cyclooxygenase 2, and exhibit defective phagocytosis and chemotaxis[81]. Rupture of microvessels within the atherosclerotic plaque releases erythrocytes, which can be phagocytosed by macrophages, and then induce these cells into M(Hb) and Mhem phenotypes[82,83]. In vitro, stimulation of human monocytes by the hemoglobin-haptoglobin complex induces M(Hb) phenotype macrophages, which produce anti-inflammatory factors, such as cytokine IL-10, by activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT/PKB) signaling pathway[82,84-86]. These cells have increased activity of liver X receptor (LXR) α and ABC transporters, which result in increased cholesterol...
efflux and reduced lipid accumulation. Furthermore, they have increased ferroportin expression, which reduces intracellular iron accumulation upon iron exposure\cite{82,87}. During hemorrhage, erythrocytes are released and scavenged by macrophages, causing an elevation in iron content and release of heme, which drive macrophages towards a Mhem phenotype\cite{88,89}. M4 macrophages are activated by the chemokine C-X-C motif ligand (CXCL) 4, and they are characterized by expression of MMP-7 and the calcium binding protein S100A8. These cells display pro-inflammatory and pro-atherogenic properties\cite{90}.

The distribution of macrophage subtypes in the atherosclerotic lesion is not uniform. In human atherosclerotic plaques, M1 macrophages are located at the rupture-prone shoulders of mature plaques, while the M2 macrophages are away from the lipid core\cite{10,91}. Macrophages in the fibrous cap surrounding the necrotic core seem to express equal numbers of M1 and M2 markers\cite{10}. Accumulating studies suggested that pro-inflammatory M1 macrophages predominate in progressing atherosclerosis, whereas atheroprotective M2 macrophages are dominant in regressing plaques\cite{11,92,93}. Functionally, M1 macrophages induce plaque inflammation, while M2 macrophages scavenge apoptotic cells and cell debris, improving tissue repair and healing\cite{70,75,94}. Therefore, plaque M2 macrophages contribute to not only the maintenance of efficient efferocytosis but also the resolution of inflammation\cite{95,96}. For instance, in the hemorrhagic areas of atherosclerotic plaques, ingestion of iron by M1 macrophages results in an uncontrolled pro-inflammatory phenotype and impairs wound healing, while M2 macrophages phagocytose both apoptotic cells and senescent erythrocytes via elevating ferroportin expression\cite{94,97,98}.

In advanced plaques, macrophages promote elastic fiber degradation and thinning of the fiber cap by increasing the production of matrix metalloproteinases\cite{99}. These products cause macrophage invasion and tissue destruction, thereby contributing to the progression and even rupture of atherosclerosis\cite{99,100}. Furthermore, M1 macrophages promote the initial calcium deposition in the necrotic core, named as microcalcification, whereas M2 macrophages promote the formation of macrocalcification by inducing osteoblast differentiation and mature of vascular smooth muscle cells. Macrocalcification induced by M2 macrophage leads to stable plaque, while microcalcification induced by M1 macrophages may lead to plaque rupture\cite{101-103}. It seems that the evolution and regression/stabilization of plaques is associated in general with the prevalence of M1 and M2 macrophages, respectively. However, the biology of atherosclerotic plaques is very complex and involves myriad cellular, soluble, and functional factors that are still far from being completely deciphered. Given the fact that M2 phenotype macrophages are not always protective\cite{80}, the biological mechanisms underlying these phenomena are much more complex and not exclusively linked to macrophage phenotypes.

**MACROPHAGE METABOLISM AND POLARIZATION**

Metabolism is a network of biochemical reactions required to generate energy and other metabolic products. Despite the plasticity of the metabolic network, macrophages generally prefer particular metabolic pathways to match their functions\cite{104}. In recent years, accumulating data suggest different metabolic microenvironments may finally regulate macrophage polarization through signaling cascades and epigenetic reprogramming. The metabolic characteristics of M1 and M2 macrophages are shown in Figures 1 and 2, respectively.

Glycolysis is termed as the anaerobic breakdown of glucose into two molecules of pyruvate and ATP. In the following, pyruvate is converted into lactate under anaerobic conditions (also known as Warburg effect), and it is converted into acetyl coenzyme A and enters tri-carboxylic acid (TCA) cycle under aerobic
Figure 1. M1 macrophage metabolism. M1 macrophage metabolism is characterized by enhanced glycolysis and increased flux through the pentose phosphate pathway (PPP) to produce NADPH, which is used to produce the inflammatory mediators nitric oxide (NO) and reactive oxygen species (ROS). In M1 macrophages, the tricarboxylic acid (TCA) cycle is truncated, which leads to the accumulation of succinate and citrate metabolites. Succinate accumulation leads to stabilization of hypoxia-inducible factor 1 alpha (HIF-1α) and transcription of pro-inflammatory and glycolytic genes, whereas citrate is used for synthesis of fatty acids. ACLY: ATP-citrate lyase; α-KG: α-ketoglutarate; FA: fatty acid synthesizer; GLUT: glucose transporter; iNOS: inducible nitric oxide synthase; LDH: lactate dehydrogenase; MCT: monocarboxylate transporter; SLC: solute carrier.

Figure 2. M2 macrophage metabolism. M2 macrophages rely on fatty acid oxidation (or β-oxidation) and L-glutamine metabolism to fuel the TCA cycle, which provide ATP for the cells. The pentose phosphate pathway (PPP) of M2 macrophages is decreased. Arginase 1 (ARG1) is highly expressed in M2 macrophages and competes with iNOS for their substrate L-arginine, thereby reducing NO production and leading to the production of urea and L-ornithine. α-KG: α-ketoglutarate; ATP: adenosine triphosphate; CARKL: carbohydrate kinase-like protein; CPT: carnitine palmitoyl transferase; LAL: lysosomal acid lipase; ROS: reactive oxygen species; SLC3a2: solute carrier family 3 member 2; TCA: tri-carboxylic acid; UDP-GlcNAc: uridine diphosphate N-acetlyglucosamine.

conditions\cite{105}. Glycolysis provides ATP at a faster pace compared with TCA cycle. Macrophages are essentially glycolytic cells in terms of bioenergetics. M1 macrophages display a metabolic shift towards the anaerobic glycolytic pathway to meet their rapid energy requirements [Figure 1]. In atherosclerotic plaques,
hypoxia-activated hypoxia-inducible factor 1 alpha (HIF-1α), driven through NF-κB, is a key regulator of the glycolytic gene program. For instance, HIF-1α induces glucose transporter 1 (GLUT1), which is a rate-limiting glucose transporter and is upregulated in hypoxia-induced inflammatory macrophages to increase glucose levels. Of note, glycolysis routes the carbon flux into the oxidative pentose phosphate pathway (PPP), which induces the generation of ROS via NADPH oxidases. M1 macrophages are characterized by enhanced PPP due to the high glycolytic flux. Carbohydrate kinase-like protein (CARKL) stimulates PPP to its non-oxidative route, thereby reducing ROS involved in pro-inflammatory activation and contributing to the macrophage polarization. In M1 macrophages, the expression of CARKL is reduced, and overexpression of CARKL may promote macrophages to an M2 phenotype in line with the reduction of pro-inflammatory cytokines. Furthermore, NADPH generated by PPP is a cofactor for inducible nitric oxide synthase (iNOS) to catabolize arginine and can be used to produce the antioxidant glutathione that plays a key role in maintaining redox homeostasis. Therefore, NADPH can be used for nitric oxide (NO) and ROS production and may also support the redox balance in M1 macrophages. Except for energy source, lactate, the metabolic by-product of glycolysis, plays a key role in histone lactylation. Compared to M1 macrophages, M2 macrophages display a decreased flux through the PPP and lower glycolytic rates. Furthermore, glycolytic stimulation may not be a requirement for M2 macrophage differentiation.

M2 macrophages sustain ATP production through the TCA cycle due to slower rates of aerobic glycolysis. It is suggested that M1 macrophages mainly depend on the TCA cycle for ROS generation, while M2 macrophages mainly relies on the TCA cycle for energy. In M1 macrophages, TCA cycle is truncated, which leads to the accumulation of succinate and citrate metabolites. Citrate in M1 macrophages promotes the synthesis of the characteristic metabolite itaconic acid, which is an inducer for intracellular succinate accumulation. Of note, the accumulated succinate can stabilize HIF-1α via induction of ROS and increased glycolytic flux, as reviewed by Geeraerts et al. In macrophages, HIF-1α regulates the expression of iNOS, which acts on L-arginine and promotes the production of the inflammatory factor NO and L-citrulline, contributing to the macrophage polarization towards the pro-inflammatory M1 phenotype. Interestingly, the product NO orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. Furthermore, LPS-induced succinate stabilizes HIF-1α and contributes to IL-1β production during inflammation. On the contrary, HIF2α is suggested to be associated with an M2 phenotype macrophages. Of note, HIF2α can regulate the transcription of ARG1, which is highly expressed in M2 macrophages and completes with iNOS for their substrate L-arginine, thereby reducing NO production and leading to the production of urea and L-ornithine. L-ornithine is a precursor of L-proline, which can be used for collagen synthesis, thereby contributing to wound healing. Interestingly, the TCA cycle undergoes a two-stage remodeling in response to LPS and INF-γ stimulation; this metabolic reprogramming provides insights into how changing metabolism can regulate the functional transitions in macrophages.

The nonoxidative PPP provides intermediates used for nucleotide and amino acid synthesis. Citrate can be exported from the mitochondria and used for fatty acid synthesis through several enzymes, as recently reviewed by Ménégaut et al. For example, citrate-derived acetyl-CoA can regulate the activation of chromatin-modifying enzymes and the biosynthesis of fatty acids. Of note, M1 macrophages are associated with the activation of fatty acid synthesis due to the increased substrate availability and upregulated genes that encode fatty acid synthesis. Due to the important role of citrate, M1 macrophages develop mechanisms to maintain the high intracellular citrate levels. However, fatty acid synthesis mediated by fatty acid synthase may induce the expression of pyrin domain containing 3 (NLRC3) and secretion of IL-1β, contributing to increased inflammation. For instance, glycine made from serine can induce glutathione synthesis, which results in IL-1β production. Excessive HIF-1α-mediated fatty acid and triglyceride synthesis may also
induce neutral lipid storage and foam cell formation\textsuperscript{114}. Presently, most studies suggest that fatty acid synthesis in macrophages may be proatherogenic. The effects of amino acids on macrophage polarization were recently reviewed by Kieler \textit{et al.}\textsuperscript{118}.

Mitochondrial oxidative phosphorylation is the primary mode of cellular energy production. However, this process is blocked in activated M1 macrophages, rendering them unable to be converted into M2 phenotype\textsuperscript{106}. Mitophagy alters mitochondrial metabolism and occurs during M1 macrophage polarization. Inhibition of mitophagy increases mitochondrial mass and decreases the expression of glycolysis genes and inflammatory responses\textsuperscript{119}. M2 macrophages have more mitochondria and increased oxygen consumption rates when compared to M1 macrophages. These differences provide M2 macrophages with great plasticity\textsuperscript{105}. Blocking oxidative metabolism not only blocks the M2 phenotype but also drives the macrophage into an M1 phenotype\textsuperscript{106}. It is suggested that microRNA-generating enzyme Dicer prevents atherosclerosis via enhancing fatty acid-fueled mitochondrial respiration in M2 macrophages of the apolipoprotein E-deficient mice\textsuperscript{110}. Using real-time extracellular flux analysis, M1 macrophages are demonstrated to have enhanced glycolytic and decreased mitochondrial activity, whereas M2 macrophages display high mitochondrial oxidative phosphorylation\textsuperscript{121}.

Fatty acid oxidation (also known as β-oxidation) and glutamine metabolism provide important energy sources for macrophage polarization towards an M2 phenotype. During this process, triacylglycerol-rich lipoproteins, such as LDL and VLDL, are internalized by CD36 and hydrolyzed via lysosomal acid lipases\textsuperscript{106}. Th2 cytokines can activate signal transducer and activator of transcription (STAT) 6 and the down-stream transcriptional regulators, such as peroxisome proliferator-activated receptor (PPAR) β, PPARγ, and PPARγ coactivator (PGC)-1β. In the following, PGC-1β induces macrophage programs for fatty acid oxidation and mitochondrial biogenesis, thereby priming macrophages for alternative activation and shifting macrophage towards an M2 phenotype\textsuperscript{122}. Furthermore, AMP-activated protein kinase (AMPK) may promote fatty acid oxidation by inactivating acetyl-CoA carboxylase and promoting mitochondrial biogenesis and function through PGC 1-α\textsuperscript{116}. Glutamine plays important roles in M2 macrophage polarization: (1) it fuels the TCA cycle via anaplerotic generation of α-ketoglutarate, which promotes fatty acid oxidation and Jmjd3-dependent epigenetic reprogramming of M2 genes\textsuperscript{123}; and (2) it drives the synthesis of UDP-GlcNAc, which contributes to the glycosylation of proteins, such as mannose receptor and macrophage galactose binding lectin\textsuperscript{116}. Of note, differing from the observations in mouse macrophages, IL-4 intervention does not induce an elevated gene expression associated with mitochondrial biogenesis and fatty acid oxidation in human macrophages\textsuperscript{106,116}. These differences and underlying mechanisms need to be investigated in the future.

Taken together, enhanced glucose uptake and glycolysis are key characteristics of M1 macrophages, whereas elevated fatty acid oxidation and phosphorylation are the main features of M2 macrophages. As reviewed recently, long chain non-coding RNAs may also participate in the regulation of macrophage polarization\textsuperscript{124}. The underlying mechanisms of how metabolism regulates macrophage polarization are complex and remain open\textsuperscript{125-127}. However, the development of advanced technologies, such as single-cell resolution and the metabolomics, are sure to improve our knowledge in this area.

**MACROPHAGE POLARIZATION INDUCED BY ENDOGENOUS MOLECULES**

As described above, macrophages are plastic cells that can polarize to different phenotypes upon different stimulus\textsuperscript{128-130}. The polarization of plaque macrophages is mainly determined by the dynamic microenvironment, such as cytokines, lipids, and other molecules, present in atherosclerotic plaques\textsuperscript{99,129,131,132}. According to the dichotomy, macrophages are divided into two classes: classically
activated pro-inflammatory M1 macrophages and alternatively activated anti-inflammatory M2 macrophages\(^{60,133}\). Presently, available data related to macrophage polarization are mainly focused on the switch between M1 and M2 phenotypes.

As described in the previous section, macrophage phenotype can be regulated by cytokines and growth factors present in atherosclerotic plaques\(^{128}\). Pro-inflammatory M1 macrophages are typically triggered by T helper 1 (Th1) cytokines and boost an inflammatory response, whereas M2 macrophages are mainly induced by Th2 cytokines and counterbalance inflammation via producing anti-inflammatory cytokines\(^{60,135,136}\). IL-4 cytokine could polarize macrophages to the M2a phenotype resident in areas of neovascularization and stable plaques\(^{20,94,135}\). Granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor are important growth factors regulating differentiation and polarization of macrophages. GM-CSF induces M1 macrophage through promoting the expression of PPBP (also known as CXCL7) and AKT2/extracellular signal-regulated kinase (ERK)/NF-κB and Janus kinase (JAK) 2/STAT5 pathways, whereas M-CSF induced M2 phenotypes through enhancing PI3K/ERK/SP1 pathway and blocking NF-κB via PI3K/AKT1 pathway\(^{116,137-141}\). The dynamic ratio of GM-CSF and M-CSF might determine the macrophage polarization\(^{140,142}\). In atherosclerotic plaques, another stimulus for macrophage polarization is intraplaque hemorrhage that occurs after vessel rupture in the areas of neovascularization, as mentioned above\(^{107,98,143}\).

During the progression of atherosclerosis, deposition of ox-LDL and other oxidized lipoproteins induces M1 polarization through activation of a TLR4-mediated pathway and inhibition of the transcription factor Krüppel-like factor (KLF) 2\(^{144-146}\). Cholesterol crystals during the early stages of the atherosclerotic plaques induce polarization of the M1 phenotype through activation of IL-1 and IL-18 by inducing the caspase-1-activated NLRP3 inflammasome\(^{147,148}\). Cholesteryl esters, including linoleate and 7-etocholesteryl-9-carboxynonanoate, can also polarize macrophages to M1 phenotype via activation of the TLR-4 and/or NF-κB signaling pathways\(^{149,150}\). Sphingomyelin on the membranes can produce sphingosine-1-phosphate (S1P), and its interaction with S1P receptor 2/3 may induce macrophage M1 polarization via PI3K/JNK pathway and exhibit proatherogenic\(^{151,152}\). However, a major product of cholesteryl ester oxidation, 9-oxononanoyl cholesterol, induces the polarization of anti-inflammatory macrophage phenotype through increasing secretion of TGF-β\(^{153}\). Additionally, conjugated linoleic acids, a set of natural isomers of linoleic acid, are found to promote an anti-inflammatory M2 subtype through increasing the production of IL-10\(^{153,154}\). S1P is known to convert M1 phenotype macrophages to M2 through activation of S1P receptor 1, which may activate ERK/CSF1 signaling and STAT3/β\(^{155-157}\). Screwing the macrophage phenotype towards an M2 phenotype is also mediated by 03-polyunsaturated fatty acid derivatives, such as resolvin D1\(^{158,159}\).

It should be noted that many molecules may participate in macrophage polarization. For example, myeloid DAP12-associating lectin-1 (MDL-1), also called CLEC5A, is positively correlated with the severity of atherosclerosis and M1 macrophages markers. MDL-1 overexpression could maintain macrophage survival, downregulate cleaved caspase-3 expression, and induce MCP-1 production under atherosclerotic microenvironment stimuli (e.g., ox-LDL and hypoxia) during early atherosclerotic plaque progression\(^{160}\). A subunit of the Skp-Cullin-F-box ubiquitin E3 ligase device, called FBXO3, is also associated with inflammatory response of macrophages upon ox-LDL stimuli\(^{161}\). Of note, galectin-3, also known as Mac-2, is a β-galactoside-binding lectin highly and constitutively expressed on plaque macrophages and displays a soluble form in the tissue microenvironment and plasma\(^{162,163}\). This lectin-molecule has been proposed for imaging atherosclerotic lesions in vivo using \(89\text{Zr}\)-DFO-Galectin 3-F(ab’2) mAb PET/CT. This novel method can image atherosclerotic plaques at different stages and has potential application for clinical detection of atherosclerosis\(^{164}\). Functionally, galectin-3 acts as an opsonin and enhances macrophage
efferocytosis of apoptotic cells\textsuperscript{[165,166]}. In M1 macrophages, galectin-3 endocytosis is receptor mediated and carbohydrate independent, whereas, in M2 macrophages, this process is carbohydrate recognition domain mediated\textsuperscript{[167]}. Furthermore, the expression and secretion of galectin-3 is associated with fibrosis and wound healing\textsuperscript{[168,169]}. A recent study demonstrated that loss of galectin-3 is associated with increased expression of proinflammatory genes, and MMP12-dependent cleavage of galectin-3 may promote proinflammatory macrophage polarization\textsuperscript{[162]}. Furthermore, the IL-10-STAT3-galectin-3 axis plays an important role in regulation of alternative activated macrophages\textsuperscript{[170,171]}. However, previous studies suggested that galectin-3 has both pro- and anti-atherosclerotic roles\textsuperscript{[172-174]}. The modulatory mechanisms of these molecules need to be investigated in the future. Collectively, the atherosclerotic plaque microenvironment impacts the macrophage phenotypes, which in turn affect plaque microenvironment due to their different biological functions and secretion of pro- and anti-inflammatory factors, contributing to atherosclerotic plaque progression and regression\textsuperscript{[165,175]}

**SIGNALING PATHWAYS INVOLVED IN MACROPHAGE POLARIZATION**

Based on their working mechanisms, the polarization of macrophages is modulated through the activation of transcription factors and signaling pathways, and the receptors respond to different inducers. For example, direct injection of inflammatory proteins is related to the acceleration of atherosclerotic plaque formation by polarization of M1 macrophages in a porcine atherosclerosis model\textsuperscript{[176]}. The key pathways in macrophage polarization are STATs, PI3K/AKT, NF-κB, and MAPKs pathways\textsuperscript{[177]}. It is worth noting that different PI3K/AKT isoforms have different functions in the activation of M1 and M2 macrophage polarization\textsuperscript{[178-181]}. Upon macrophage M1 polarization, MAPKs, STAT-1/2, NF-κB, and other signaling pathways are activated, thereby promoting M1-related genes expression\textsuperscript{[182,183]}. IL-4 induced M2 polarization is associated with the activation of STAT3/6 or PI3K/AKT, which promote M2 genes expression\textsuperscript{[182-184]}

The major pathways that participated in M1 macrophage polarization are summarized in Figure 3. In response to an inflammatory environment, TLR4 is activated, which stimulates intracellular signaling cascades, including MAPK and NF-κB transducers, contributing to the expression of inflammatory cytokines, such as TNF-α, IL-6, and IL-12\textsuperscript{[185]}. IFN-γ-mediated JAK-STAT1/2 signaling also promotes M1 macrophage polarization\textsuperscript{[185]}. Theoretically, molecules that positively regulate these pathways may promote macrophage polarization towards an M1-like phenotype. For example, triggering receptor expressed on myeloid cells (TREM-1) is expressed in macrophages and plays a critical role in the upregulation of CD36, thereby promoting the formation of inflammatory foam cells. Furthermore, TREM-1 promotes inflammation by activating TLR4. Genetic and pharmacological inhibition of TREM-1 reduces TLR4-initiated pro-inflammatory responses and retards the development of atherosclerosis in mice\textsuperscript{[186]}. Proprotein convertase subtilisin/kexin type 9 (PCSK9) contributes to the formation of foam cells by inducing the expression of scavenger receptors and promoting LDLR degradation in lysosomes\textsuperscript{[184]}. PCSK9 overexpression in macrophages increases the secretion of pro-inflammatory cytokines induced by ox-LDL in vitro, and the mechanisms are related to the upregulation of TLR4 and p-IκBα levels and NF-κB translocation\textsuperscript{[187]}. PCSK9 gene interference reduces vascular inflammation via inhibiting TLR4/NF-κB signaling pathway\textsuperscript{[188]}. Junction adhesion molecule-like (JAML) protein is expressed in macrophages of human and mouse atherosclerotic plaques. It regulates the activation of NF-κB and the production and secretion of inflammatory cytokines\textsuperscript{[189]}. Silencing the expression of JAML can reduce the progression of atherosclerotic plaques in mouse models\textsuperscript{[189]}. Thyroid-stimulating hormone level is an independent risk factor of atherosclerosis. Ablation of thyroid-stimulating hormone receptor inhibits the formation of atherosclerosis by reducing vascular inflammation and macrophage burden\textsuperscript{[190]}. Mechanistically, thyroid-stimulating hormone interacts with its receptor and activates MAPKs (ERK1/2, p38, and c-Jun N-terminal kinase, JNK) and IκB/p65 NF-κB pathways in macrophages, increasing the production of inflammatory cytokines and the recruitment
Figure 3. The signaling pathways involved in M1 macrophage polarization. S1P: Sphingosine-1-phosphate; PI3K: phosphoinositol 3-kinase; JNK: c-Jun NH2-terminal kinase; AKT: serine/threonine-protein kinases; mTOR: mechanistic target of rapamycin; TLR: toll-like receptors; MyD88: myeloid differentiation factor 88; OxLDL: oxidized low-density lipoprotein; LPS: lipopolysaccharide; MAPK: mitogen-activated protein kinases; ERK: extracellular regulated protein kinases; IFN-γ: Interferon-gamma; JAK: Janus kinase; STAT: signal transducers and activators of transcription; GM-CSF: granulocyte-macrophage colonystimulating factor; NFκB: nuclear factor kappa-B.

of monocytes\cite{190}. On the contrary, the anti-inflammatory NR4A1 (Nur77) receptor shows an anti-atherosclerosis effect in mice\cite{190}. The underlying mechanisms are related to the suppression of TLR4 signaling and polarization of macrophages towards an M1 phenotype by phosphorylation of p65 NF-κB\cite{191,192}. Glucose-dependent insulinotropic peptide is secreted by the gut after food intake. This incretin hormone attenuates inflammation of atherosclerotic plaques and endotoxin activated macrophages via inhibiting MAPKs (JNK, ERK, and p38) and the downstream NF-κB pathway. Furthermore, it reduces atherosclerotic plaque macrophage infiltration and MCP-1-induced monocyte migration and increases collagen content, possibly by inhibiting the activity of MMP-9\cite{193}. PPARγ agonists play an anti-inflammatory effect by antagonizing TLR4\cite{194}. Pigment epithelium-derived factor (PEDF) is an endogenous cytokine with anti-inflammatory activity. PEDF overexpression can decrease the levels of inflammatory factors and MMP-9 via inhibiting the phosphorylation of MAPKs (JNK, ERK, and p38). PPARγ specific antagonist GW9662 reduces the anti-inflammatory effect of PEDF. These results suggest that PEDF may reduce the polarization of pro-inflammatory M1 macrophages via the MAPK/PPARγ pathway\cite{195,196}. The calcium-activated potassium channel KCa3.1 is also involved in macrophage activation. In mice atherosclerotic plaques, KCa3.1 blockade therapy reduces the incidence of plaque rupture, enhances the M2 macrophage markers, and decreases macrophage polarization towards an M1 phenotype via...
downregulating STAT-1 phosphorylation\(^{[183]}\).

The major pathways involved in M2 macrophage polarization are summarized in Figure 4. IL-4- or IL-13-induced IL-4 receptor \(\alpha\) signals promote M2 macrophage polarization via the JAK/STAT6 pathway\(^{[187,190]}\). It has been demonstrated that STAT6 facilitates atherosclerotic plaque stabilization by promoting the polarization of macrophages to an M2 subtype and antagonizing ox-LDL-induced cell apoptosis and lipid deposition in a Wnt-\(\beta\)-catenin-dependent manner\(^{[177]}\). KLF4 coordinates with STAT6 to promote M2 genetic program, and it inhibits M1 macrophage polarization via blocking NF-\(\kappa\)B pathway\(^{[196]}\). Lack of KLF4 enhances M1 gene expression and promotes pro-inflammatory activation and foam cell formation \textit{in vitro}\(^{[198]}\). Deletion of KLF4 promotes inflammation and atherosclerotic plaque formation \textit{in vivo}\(^{[199]}\).

Kallistatin, a tissue kallikrein-binding protein and a serine protease inhibitor, reduces atherosclerotic plaque formation in apolipoprotein E-deficient mice. Mechanistically, kallistatin increases the expression of IL-10 and ARG1 that are associated with M2 macrophages and decreases iNOS and monocyte chemotactic protein 1 that are associated with M1 macrophages in a KLF4-dependent manner\(^{[200]}\).

The activation of IL-4 receptor \(\alpha\) and other factors may trigger PI3K/AKT signaling, thereby contributing to the M2 macrophage polarization\(^{[183,201]}\). Here again, we need to point out that distinct PI3K/AKT isoforms play distinct roles in activating macrophage polarization. Class I PI3K/AKT1 and Class III PI3K/AKT2 may promote M2 and M1 macrophage polarization, respectively\(^{[178-181]}\). miRNAs also participate in macrophage polarization. For instance, miR-135b promotes inflammation in atherosclerotic plaques, while its inhibition attenuates inflammation via inactivating the PI3K/Akt signaling pathway\(^{[202]}\). Furthermore, activation of PPAR\(\gamma\) by its endogenous agonists, such as by fatty acids, can antagonize the activities of the transcription factors STAT and NF-\(\kappa\)B, contributing to the anti-inflammatory effect in macrophages\(^{[201]}\). Of note, ligand-dependent SUMOylation of the PPAR\(\gamma\) ligand-binding domain is important for PPAR\(\gamma\)-mediated suppression of inflammatory response\(^{[204]}\). IL-19 treatment induces a reduction in plaque macrophage numbers and an enrichment in M2 macrophage markers, suggesting an atherosclerosis regression\(^{[205]}\). Mechanistic studies revealed that IL-19 or recombinant IL-19 promotes the activation of the key pathways involved in M2 macrophage polarization, including STAT3/6, KLF4, and PPAR\(\gamma\) \textit{in vivo}\(^{[195,200-207]}\).

Additionally, bone morphogenetic proteins, members of the TGF-\(\beta\) superfamily, play a key role in cell fate and differentiation\(^{[206,208]}\). For instance, bone morphogenetic protein-7 directs cellular plasticity, specifically THP-1 monocytes differentiation into M2 macrophages, and enhances the levels of anti-inflammatory cytokines \textit{in vitro}. Furthermore, this molecule can inhibit plaque formation \textit{in vivo}\(^{[209,210,211]}\).

Finally, ABC transporters also contribute to macrophage polarization towards an M2 phenotype by promoting cholesterol efflux and the subsequent reduction of inflammation. Human atherosclerotic plaques contain a relatively high concentration of desmosterol, which is an endogenous LXR agonist even in the absence of sterol hydroxylases. LXR activation promotes the expression of ABC transporters, thereby enhancing cholesterol efflux accompanied with anti-inflammatory effect. These data suggest that desmosterol might promote macrophage polarization towards an M2 phenotype\(^{[212]}\). miR-23a-5p is positively correlated with plaque progression and vulnerability. Transfection of miR-23a-5p inhibitors can increase the expression of ABCA1/G1 to promote cholesterol efflux and reduce the formation of foam cells\(^{[213]}\). Therefore, lipid-lowering may enhance macrophage polarization towards an M2 phenotype by improving the plaque microenvironment.

**TREATMENT DIRECTED MACROPHAGE POLARIZATION**

Presently, lipid-lowering strategies cannot completely inhibit atherosclerosis. Macrophages are involved in all stages of this chronic and multifaceted disease. As described above, the dynamic atherosclerotic plaque
Figure 4. The signaling pathways involved in M2 macrophage polarization. S1P: Sphingosine-1-phosphate; PI3K: phosphoinositide 3-kinase; AKT: serine/threonine-protein kinases; mTOR: mechanistic target of rapamycin; ERK: extracellular regulated protein kinases; JAK: janus kinase; STAT: signal transducers and activators of transcription; M-CSF: macrophage colony stimulating factor; NFκB: nuclear factor kappa-B; SP1: specificity protein 1; IL: interleukin; AMPK: AMP-activated protein kinase; PPAR: peroxisome proliferator-activated receptor; RTK: receptor tyrosine kinase; TGF-β: transforming growth factor-β; CSF1: colony-stimulating factor 1; CXCL: chemokine (C-X-C motif) ligand; GPCR: G-protein-coupled receptor; KLF4: kruppel-like factor 4.

microenvironment determines the activation states of the macrophages. More importantly, macrophages have a good plasticity and play key roles in plaque instability and regression[214,215]. Therefore, a new idea for the treatment of atherosclerosis is through regulating macrophage polarization from the pro-atherogenic M1 phenotype to the anti-atherogenic M2 phenotype. Theoretically, compounds that regulate the dynamic plaque microenvironment or trigger the signaling pathways involved in macrophage polarization may promote macrophage phenotype shift, contributing to the progression or regression of atherosclerosis.

Melatonin, an indoleamine hormone, shows cardioprotective activity in several animal models[216-220]. Of note, this molecule can inhibit the development of atherosclerosis[221]. Mechanistically, melatonin ameliorates intraplaque inflammation by suppressing macrophage differentiation towards the pro-inflammatory M1 phenotype and improving M2 macrophage polarization as well as RORα-mediated anti-inflammatory effects in vulnerable plaques[222]. It is suggested that the melatonin-RORα axis regulates macrophage polarization by differentially regulating the AMPKα/STATs pathway[222]. The natural product Ginsenoside Rb1 reduces M1 macrophage markers and increases M2 macrophage markers via promoting phosphorylation of STAT6 in vitro. This molecule enhances plaque stability by promoting the anti-inflammatory M2 macrophage polarization in an STAT6-dependent manner in apolipoprotein E-deficient mice[223,224].

Oleylethanolamide (OEA), an endogenous PPARα agonist, enhances the expression of two classic M2 macrophage markers, CD206 and TGF-β, and decreases the expression of iNOS, an M1 macrophage marker, in THP-1-derived macrophages[225,226]. More importantly, OEA inhibits M1 macrophage polarization in atherosclerotic plaques and promotes the polarization of M2 macrophages through
AMPK/PPARα/STAT3 pathway\(^{225,226}\). Blocking of PPARα using siRNA or inhibition of AMPK by its inhibitor attenuates the OEA-induced expression of M2 macrophage markers\(^{225,226}\). Furthermore, OEA increases collagen content and decreases necrotic core size in atherosclerotic plaques in mice via PPARα\(^{225,226}\). Ginsenoside Rg3 (GRg3) has potential vascular protective effects. *In vitro* study demonstrated that GRg3 reverses the macrophage polarization towards an M1 phenotype induced by advanced glycation end-products. *In vivo*, it improves the stability of atherosclerotic plaques, reduces M1 macrophages, and increases M2 macrophages through the PPARγ pathway\(^{227}\). These results suggest that PPARα or PPARγ agonists have potential effects on promoting M2 macrophage polarization.

Natural products exhibit attractive effects on promoting macrophage polarization towards an M2 phenotype. Curcumin, a polyphenol component in turmeric, has multiple pharmacological activities, including regulation of cholesterol homeostasis, inflammatory response, and especially modulatory effects on macrophage polarization\(^{228-231}\). *In vitro* data indicate that curcumin inhibits polarization of RAW264.7 cells (M0) to M1 phenotype and switch M1 or M0 macrophages to the M2 phenotype\(^{229}\). Mechanistically, curcumin could suppress M1 inflammatory phenotype through activation of IkBa in M0 macrophages and promote polarization of M1 or M0 phenotypes to M2 macrophages through activation of PPAR-γ\(^{228,229}\). Furthermore, accumulating studies demonstrated that curcumin shifts M1 macrophages to an M2 phenotype via downregulating TLR4 and the phosphorylation of MAPKs (ERK, JNK, and p38) and NF-κB\(^{226-229}\). The polyphenols of pomegranate inhibit the inflammatory response of macrophages and promote macrophage switch from M1 to M2 phenotype, contributing to their anti-inflammatory and anti-atherosclerosis effects in mice\(^{233}\). These results indicate that polyphenols are effective at promoting M2 macrophage polarization. Furthermore, tanshinone IIA and astragaloside IV, two compounds from traditional Chinese medicine, reinforce plaque stability via activating PI3K/AKT and inhibiting TLR4/NF-κB signaling that are involved in modulating macrophage polarization\(^{234}\).

Some synthesized compounds or clinically used drugs also induce macrophage polarization. Activated factor X contributes to the pathophysiology of chronic inflammation besides its roles in coagulation cascade. Rivaroxaban, an inhibitor of factor X, can inhibit inflammation in the atherosclerotic plaques and in RAW264.7 macrophages except for its antithrombotic effect\(^{225}\). Angiotensin 1-7 exhibits cardiovascular protective effect, and its non-peptide mimic AVE0991 can inhibit monocytes/macrophages differentiation towards an M1 phenotype and their recruitment to the perivascular space, thereby retarding inflammation and early atherosclerosis\(^{226}\). Dipeptidyl peptidase inhibitors used for treating patients with type 2 diabetes have been found to reduce cholesterol levels and downregulate the formation of atherosclerosis\(^{234,238}\). Mechanistically, these inhibitors may promote monocyte polarization towards M2 macrophages through the SDF-1/CXCR4 signaling pathway\(^{238}\). Additionally, treatment with RXRα modulator K-80003 decreases 7-ketocholesterol-induced p65 nuclear translocation, IkBa degradation, and transcription of NF-κB target genes, contributing to the reduced plaque size, plaque rupture, macrophage infiltration, and inflammatory cytokine levels\(^{238}\). Finally, we should pay attention to some drugs that can promote macrophage polarization towards M1 phenotype. For instance, doxorubicin, a drug used to treat cancers, induces adverse cardiotoxic effects. Mechanistically, doxorubicin treatment increases expression of TLR4 and NLRP3 and downstream MAPK cell signaling proteins, such as MyD88, p-P38, and p-JNK, contributing to the polarization of pro-inflammatory M1 macrophages and secretion of inflammatory cytokines\(^{240}\). These drugs need to be carefully used when patients are suffering from cardiovascular disease and cancer at the same time.
CONCLUSIONS AND PERSPECTIVES

Macrophages play important roles in the progression and regression of atherosclerosis, and each subtype of macrophage has distinct functions. These heterogenous and plastic cells can switch from one phenotype to another in response to distinct microenvironmental stimuli, which differentially activate the signaling pathways involved in macrophage polarization. Accumulating data demonstrate that macrophage polarization towards the atheroprotective M2 phenotype may contribute to plaque stability and regression. Theoretically, molecules that positively regulate M2 polarization and/or negatively modulate M1 polarization may benefit atherosclerosis stability and regression. These findings provide a hope for reversing this chronic disease because the present therapeutic strategies cannot completely retard the progression of atherosclerosis. Of note, there are still many questions that need to be resolved to reach this clinical goal.

Macrophages can undergo distinct polarization states, but we do not clearly know the functions of each subtype. At present, the majority of available data are limited to the M1 and M2 phenotypes, which have been simply classified a decade ago. It is worth noting that M2 phenotype macrophages are not always protective, which further increases the complexity of macrophage phenotype and function. Combined proteomic and transcriptomic single-cell analysis is likely to resolve this problem. Furthermore, most studies are carried out in rodents, whose macrophage phenotypes and atherosclerosis progression are different from ours. Therefore, these data cannot be translated directly into clinical application. Novel technologies, such as non-invasive detection, are needed to improve our understanding of human macrophage phenotypic diversity and its roles in atherosclerotic plaques.

DECLARATIONS

Authors’ contributions

Performed reference collection and wrote the manuscript: Liu N, Zhang B, Sun Y
Re-edited the manuscript: Song W, Guo S

Availability of data and materials

Not applicable.

Financial support and sponsorship

This work was supported by the Natural Science Foundation of China (81770463, 82070469, 31300639).

Conflicts of interest

Not applicable.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2021.

REFERENCES

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26. DOI PubMed
2. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013;13:709-21. DOI PubMed PMC
3. Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res 2016;118:653-67. DOI PubMed PMC
Saha AK, Osmulski P, Dallo SF, Gaczynska M, Huang TH, Ramasubramanian AK. Cholesterol regulates monocyte rolling through...

Liu et al. Vessel Plus 2021;5:43  |  https://dx.doi.org/10.20517/2574-1209.2021.25  Page 17 of 24

4. Amengual J, Barrett TJ. Monocytes and macrophages in atherogenesis. Curr Opin Lipidol 2019;30:401-8. DOI PubMed PMC
5. Bories GF, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett 2017;591:3042-60. DOI PubMed
6. Montzafi-Borjeni AA, Abdollahi E, Nikfar B, Chaichian S, Ekhlassi-Hundrieser M. Curcumin as a potential modulator of M1 and M2 macrophages: new insights in macrophages in atherosclerosis therapy. Heart Fail Rev 2019;24:399-409. DOI PubMed
7. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995;92:8264-8. DOI PubMed PMC
8. Glass CK, Witzum JL. Atherosclerosis. Cell 2001;104:503-16. DOI PubMed
9. Tsaousi A, Hayes EM, Di Gregoli K, et al. Plaque size is decreased but M1 macrophage polarization and rupture related metalloproteinase expression are maintained after deleting T-Bet in ApoE null mice. PLoS One 2016;11:e0148873. DOI PubMed PMC
10. Stöger JL, Gijbels MJ, van der Velden S, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012;225:461-8. DOI PubMed
11. Cho KY, Miyoshi H, Kuroda S, et al. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis 2013;22:910-8. DOI PubMed
12. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. Eur J Vasc Endovasc Surg 2012;44:491-7. DOI PubMed
13. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: The role of PCSK9. Arch Biochem Biophys 2017;625-626:39-53. DOI PubMed PMC
14. Geissmann F, Jung S, Littrman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82. DOI PubMed
15. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64. DOI PubMed
16. Kim H. The transcription factor MaFb promotes anti-inflammatory M2 polarization and cholesterol efflux in macrophages. Sci Rep 2017;7:7591. DOI PubMed PMC
17. Solanki S, Dube PR, Birnbaumer L, Vazquez G. Reduced necrosis and content of apoptotic M1 macrophages in advanced atherosclerotic plaques of mice with macrophage-specific loss of Trpc3. Sci Rep 2017;7:42526. DOI PubMed PMC
18. Paul A, Lydic TA, Hogan R, Goo YH. Cholesterol acceptors regulate the lipidome of macrophage foam cells. Int J Mol Sci 2019;20:3784. DOI PubMed PMC
19. Medbury JJ, Tarran SL, Guijre AK, Williams MM, Lam TH, et al. Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes. Int Angiol 2008;27:114-23. PubMed
20. Bouhel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007;6:137-43. DOI PubMed
21. Chistiakov DA, Bobryshev YV, Nikiforov NG, Elizova NV, Sobenin IA, Orekhov AN. Macrophage phenotypic plasticity in atherosclerosis: The associated features and the peculiarities of the expression of inflammatory genes. Int J Cardiol 2015;184:436-45. DOI PubMed
22. Adamson S, Leitinger N. Phenotypic modulation of macrophages in response to plaque lipids. Curr Opin Lipidol 2011;22:335-42. DOI PubMed PMC
23. Nagenborg J, Goossens P, Biessen EAL, Donners MMPC. Heterogeneity of atherosclerotic plaque macrophage origin, phenotype and functions: Implications for treatment. Eur J Pharmacol 2017;816:14-24. DOI PubMed
24. Guo S, Xia X, Gu H, Zhang D. Proprotein convertase subtilisin/kexin-type 9 and lipid metabolism. Adv Exp Med Biol 2020;1276:137-56. DOI PubMed PMC
25. She ZG, Hamzah J, Kotamraju VR, Pang HB, Jensen S, Ruolahiti E. Plaque-penetrating peptide inhibits development of hypoxic atherosclerotic plaque. J Control Release 2016;238:212-20. DOI PubMed
26. Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity 2017;47:621-34. DOI PubMed PMC
27. Rahman MS, Murphy AJ, Woollard KJ. Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. Annu Rev Immunol 2016;34:1-32. DOI PubMed
28. Mildner A, Marinkovic G, Jung S. Murine monocytes: origins, subsets, fates, and functions. Microbiol Spectr 2016;4. DOI PubMed
29. Jia SJ, Gao KQ, Zhao M. Epigenetic regulation in monocyte/macrophage: A key player during atherosclerosis. Cardiovasc Ther 2017;35:e12262. DOI PubMed
30. Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical monocytes in health and disease. Annu Rev Immunol 2019;37:439-56. DOI PubMed
31. Splitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell 2016;165:780-91. DOI PubMed PMC
32. Xiang GA, Zhang YD, Su CC, et al. Dynamic changes of mononuclear phagocytes in circulating, pulmonary alveolar and interstitial compartments in a mouse model of experimental silicosis. Inhal Toxicol 2016;28:393-402. DOI PubMed
33. Hamers AAJ, Dinh HQ, Thomas GD, et al. Human monocyte heterogeneity as revealed by high-dimensional mass cytometry. Arterioscler Thromb Vasc Biol 2019;39:25-36. DOI PubMed PMC
34. Villani AC, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017;356:eaab4573. DOI PubMed PMC
35. Wildgruber M, Aschenbrenner T, Wendorff H, et al. The "Intermediate" CD14++CD16- monocyte subset increases in severe peripheral artery disease in humans. Sci Rep 2016;6:39483. DOI PubMed PMC
36. Saha AK, Osmulski P, Dallo SF, Gaczynska M, Huang TH, Ramasubramanian AK. Cholesterol regulates monocyte rolling through CD44 expression. Biophys J 2017;112:1481-8. DOI PubMed PMC
Yang R, Liao Y, Wang L, et al. Exosomes derived from M2b macrophages attenuate DSS-induced colitis.}

24. Tolani S, Pagler TA, Murphy AJ, et al. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FI children. Atherosclerosis 2013;229:79-85. DOI PubMed PMC

25. Schnitzler JG, Bernelot Moens SJ, Tiessen F, et al. Nile Red Quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. J Lipid Res 2017;58:2210-9. DOI PubMed PMC

26. Christensen JJ, Osnes LT, Halvorsen B, et al. Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia. Atherosclerosis 2017;256:67-74. DOI PubMed

27. Combadière C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes hypercholesterolemia in mice. Circulation 2008;117:1649-57. DOI PubMed

28. Murphy AJ, Tall AR. Disordered haematopoiesis and athero-thrombosis. Eur Heart J 2016;37:1113-21. DOI PubMed PMC

29. Fernandez-Ruiz I, Puchalska P, Narasimhulu CA, Sengupta B, Parhasarathy S. Differential lipid metabolism in monocytes and macrophages: influence of cholesterol loading. J Lipid Res 2016;57:574-86. DOI PubMed PMC

30. Liu Z, Saeed A, Peng X, et al. Monocyte phenotyping and management of lipoprotein X syndrome. J Clin Lipidol 2020;14:850-8. DOI PubMed PMC

31. Bekkering S, Stiekema LCA, Bernelot Moens S, et al. Treatment with Statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab 2019;30:1-2. DOI PubMed

32. Li W, Sultana N, Siraj N, et al. Autophagy dysfunction and regulatory cystatin C in macrophage death of atherosclerosis. J Cell Mol Med 2016;20:1664-72. DOI PubMed PMC

33. Tjaden K, Adam C, Godfrey R, Hanley PJ, Pardali E, Waltenberger J. Low density lipoprotein interferes with intracellular signaling of monocytes resulting in impaired chemotaxis and enhanced chemokinesis. Int J Cardiol 2018;255:160-5. DOI PubMed

34. Bahrami A, Liberale L, Reiner Ž, Carbone F, Montecucco F, Sabbekar A. Inflammatory biomarkers for cardiovascular risk stratification in familial hypercholesterolemia. Rev Prisul Biochem Pharmacol 2020;177:25-52. DOI PubMed PMC

35. Wang Y, Dubland JA, Allahverdian S, et al. Smooth muscle cells contribute the majority of foam cells in ApoE (Apolipoprotein E)-deficient mouse atherosclerosis. Atherosclerosis Thromb Vasc Biol 2019;39:876-87. DOI PubMed PMC

36. Rendra E, Riabov V, Mossel DM, Levendosky L, Attacks J, AP9. Inflammatory biomarkers for cardiovascular risk in patients with inflammatory bowel disease. J Atheroscler Thromb 2019;26:299-313. DOI PubMed PMC

37. Dekker A, Davis FM, Kunkel SL, Gallagher KA. Targeting epigenetic mechanisms in diabetic wound healing. Transl Res 2019;204:39-50. DOI PubMed PMC

38. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019;4:131774. DOI PubMed PMC

39. Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1α/Glycolysis-dependent axis. Cell Metab 2020;32:498-9. DOI PubMed PMC

40. Ikeda Y, Sonoda N, Bachuluun B, Kimura S, Ogawa Y, Inoguchi T. Aberrant activation of bone marrow Ly6C high monocytes in children with familial hypercholesterolemia. Atherosclerosis 2017;263:377-84. DOI PubMed

41. Barrett TJ, Distel E, Murphy AJ, et al. Apolipoprotein AI promotes atherosclerosis regression in diabetic mice by suppressing myelopoesis and plaque inflammation. Circulation 2019;140:1170-84. DOI PubMed PMC

42. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol 2013;10:219-30. DOI PubMed

43. Mehta S, Dhanaw V. Exposure of cigarette smoke condensate activates NLRP3 inflammasome in THP-1 cells in a stage-specific manner: An underlying role of innate immunity in atherosclerosis. Cell Signal 2020;72:109645. DOI PubMed

44. Kohashi K, Nakagomi A, Morisawa T, et al. Effect of smoking status on monocyte tissue factor activity, carotid atherosclerosis and long-term prognosis in metabolic syndrome. Circ J 2018;82:1418-27. DOI PubMed

45. Cheng YC, Sheen JM, Hu WL, Hung YC. Polyphenols and oxidative stress in atherosclerosis-related ischemic heart disease and stroke. Oxid Med Cell Longev 2017;2017:8526438. DOI PubMed PMC

46. de Ronde MWJ, Kok MGM, Moerland PD, et al. High mir-124-3p expression identifies smoking individuals susceptible to atherosclerosis. Atherosclerosis 2017;263:377-84. DOI PubMed

47. Mehta S, Srivastava N, Bhataia A, Dhanaw V. Exposure of cigarette smoke condensate activates NLRP3 inflammasome in vitro and in vivo: A connotation of innate immunity and atherosclerosis. Int Immunopharmacol 2020;84:106561. DOI PubMed

48. Studer RK, Negrete H, Craven PA, DeR Mauritius FR. Protein kinase C signals thromboxane induced increases in fibroblast synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 1995;48:422-30. DOI PubMed

49. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86. DOI PubMed

50. Boldrick JC, Alizadeh AA, Diehn M, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A 2002;99:972-7. DOI PubMed PMC

51. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993;259:1739-42. DOI PubMed

52. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003;73:209-12. DOI PubMed

53. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37. DOI PubMed PMC

54. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol 2014;5:614. DOI PubMed PMC

55. Yang R, Liao Y, Wang L, et al. Exosomes derived from M2b macrophages attenuate DSS-induced colitis. Front Immunol
98. Bories G, Colin S, Vanhouette J, et al. Liver X receptor activation stimulates iron export in human alternative macrophages. *Circ Res* 2013;113:1196-205. DOI PubMed PMC

99. Childs BG, Baker DJ, Wijshakke T, Conover CA, Campisi J, van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. *Science* 2016;354:472-7. DOI PubMed PMC

100. Newby AC. Metalloliproteinase production from macrophages - a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction. *Exp Physiol* 2016;101:1327-37. DOI PubMed

101. Shiio T, Ikari Y. Plaque calcification during atherosclerosis progression and regression. *J Atheroscler Thromb* 2018;25:294-303. DOI PubMed PMC

102. Reith S, Milzi A, Dettori R, Marx N, Burgmaier M. Predictors for target lesion microcalcifications in patients with stable coronary artery disease: an optical coherence tomography study. *Clin Res Cardiol* 2018;107:763-71. DOI PubMed

103. Burgmaier M, Milzi A, Dettori R, Burgmaier K, Marx N, Reith S. Co-localization of plaque macrophages with association is classified with a more vulnerable plaque phenotype and a greater calcification burden in coronary target segments as determined by OCT. *PLoS One* 2018;13:e0205984. DOI PubMed PMC

104. Geerarts X, Bolli E, Fendt SM, Van Ginderachter JA. Macrophage metabolism as therapeutic target for cancer, atherosclerosis, and obesity. *Front Immunol* 2017;8:289. DOI PubMed PMC

105. Mehla K, Singh PK. Metabolic regulation of macrophage polarization in cancer. *Trends Cancer* 2019;5:822-34. DOI PubMed PMC

106. Qing J, Zhang Z, Novák P, Zhao G, Yin K. Mitochondrial metabolism in regulating macrophage polarization: an emerging regulator of metabolic inflammatory diseases. *Acta Biochim Biophys Sin (Shanghai)* 2020;52:917-26. DOI PubMed

107. Verdeguer F, Aududi M. Macrophage heterogeneity and energy metabolism. *Exp Cell Res* 2017;360:35-40. DOI PubMed

108. Haschemi A, Kosma P, Gille L, et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. *Cell Metab* 2012;15:813-26. DOI PubMed

109. Galván-Peña S, O’Neill LA. Metabolic reprogramming in macrophage polarization. *Front Immunol* 2014;5:420. DOI PubMed PMC

110. Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. *Nature* 2019;574:575-80. DOI PubMed PMC

111. Wang F, Zhang S, Vuckovic I, et al. Glycolytic stimulation is not a requirement for M2 macrophage differentiation. *Cell Metab* 2018;28:463-475.e4. DOI PubMed PMC

112. Palmieri EM, Gonzalez-Cotto M, Baseler WA, et al. Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. *Nat Commun* 2020;11:698. DOI PubMed PMC

113. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. *Nature* 2013;496:238-42. DOI PubMed PMC

114. Rath M, Müller I, Kroepf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. *Front Immunol* 2014;5:532. DOI PubMed PMC

115. Seim GL, Britt EC, John SV, et al. Two-stage metabolic remodelling in macrophages in response to lipopolysaccharide and interferon-γ stimulation. *Nat Metab* 2019;1:731-42. DOI PubMed PMC

116. Ménégaut L, Thomas C, Lagrost L, Masson D. Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases. *Front Physiol* 2020;11:642. DOI PubMed PMC

117. Bories G, Baker DJ, Wijshakke T, Conover CA, Campisi J, van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. *Science* 2016;354:472-7. DOI PubMed PMC

118. Liu PS, Wang H, Li X, et al. Metabolic influence on macrophage polarization and pathogenesis. *BMB Rep* 2019;52:360-72. DOI PubMed PMC

119. Biswas SK, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization and plasticity in health and disease. *Immunol Res* 2012;53:11-24. DOI PubMed

120. Porcheray F, Vialud S, Rimanoli AC, et al. Macrophage activation switching: an asset for the resolution of inflammation. *Clin Exp Immunol* 2005;142:481-9. DOI PubMed PMC
Lee et al. Vessel Plus 2021;5:43 | https://dx.doi.org/10.20517/2574-1209.2021.25

130. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011;22:317-26. DOI PubMed PMC

131. Abumaree MH, Al Jumah MA, Kalionis B, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rep 2013;9:620-41. DOI PubMed

132. Nahnrendorf M, Swirsk F. Abandoning M1/M2 for a network model of macrophage function. Circ Res 2016;119:414-7. DOI PubMed PMC

133. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35. DOI PubMed

134. Wolff IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 2011;106:763-71. DOI PubMed

135. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122:787-95. DOI PubMed PMC

136. Verreck FA, de Boer T, Langenberg DM, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci US A 2004;101:4560-5. DOI PubMed PMC

137. Trus E, Basta S, Gee K. Who’s in charge here? Cytokine 2020;127:154939. DOI PubMed

138. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 2014;6:a021857-a021857. DOI PubMed PMC

139. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13. DOI PubMed PMC

140. Brochériou I, Maouche S, Durand H, et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 2011;214:316-24. DOI PubMed

141. Woldo SW, Li Y, Buono C, et al. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008;172:1112-26. DOI PubMed PMC

142. Plenz G, Koenig C, Severs NJ, Robenek H. Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler Thromb Vase Biol 1997;17:2489-99. DOI PubMed

143. Koldogie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349:2316-25. DOI PubMed

144. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009;104:210-8, 21p following 218. DOI PubMed PMC

145. Tiss LJ, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhoef AF. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. Atherosclerosis 2011;214:345-9. DOI PubMed

146. Hirose K, Iwabuchi K, Shimada K, et al. Different responses to oxidized-low-density lipoproteins in human polarized macrophages. Lipids Health Dis 2011;10:1. DOI PubMed PMC

147. Fan A, Wu X, Wu H, et al. Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL. PLoS One 2014;9:e85337. DOI PubMed PMC

148. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherosclerosis and activated by cholesterol crystals. Nature 2010;464:1357-61. DOI PubMed PMC

149. Fang L, Harkevicz R, Hartvigsen K, et al. Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem 2010;285:32343-51. DOI PubMed PMC

150. Sottero B, Gamba P, Longhi M, et al. Expression and synthesis of TGFbeta1 is induced in macrophages by 9-oxononanoyl cholesterol, a major cholesteryl ester oxidation product. Biofactors 2005;24:209-16. DOI PubMed

151. Yang J, Yang L, Tian L, Ji X, Yang L, Li L. Sphingosine 1-phosphate (S1P)/S1P receptor2/3 axis promotes inflammatory M1 polarization of bone marrow-derived monocyte/macrophage via G(o(i)/o)PI3K/JNK pathway. Cell Physiol Biochem 2018;49:1677-93. DOI PubMed

152. Hou L, Yang L, Chang N, et al. Macrophage sphingosine 1-phosphate receptor 2 blockade attenuates liver inflammation and fibrogenesis triggered by NLRP3 inflammasome. Front Immunol 2020;11:1149. DOI PubMed PMC

153. Mitchell PL, McLeod RS. Conjugated linoleic acid and atherosclerosis: studies in animal models. Biochem Cell Biol 2008;86:293-308. DOI PubMed

154. McCarthy C, Duffy MM, Mooney D, et al. IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis. FASEB J 2013;27:499-510. DOI PubMed

155. Müller J, von Bernstorff W, Heidecke CD, Schulze T. Differential S1P receptor profiles on M1- and M2-polarized macrophages and implications for regression of atherosclerosis. Circ Res 2003;93:23-35. DOI PubMed

156. Park SJ, Lee KP, Kang S, et al. Sphingosine 1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell Signal 2014;26:2249-58. DOI PubMed

157. Kuang Y, Li X, Liu X, et al. Vascular endothelial S1P1 receptor ameliorates adverse cardiac remodelling via stimulating reparative macrophage proliferation after myocardial infarction. Cardiovasc Res 2021;117:585-99. DOI PubMed

158. Titos E, Rius B, González-Pérez A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011;187:5408-18. DOI PubMed

159. Serhan CN, Yang R, Martind K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009;206:15-23. DOI PubMed PMC

160. Xiong W, Wang H, Lu L, et al. The macrophage C-type lectin receptor CLEC5A (MDL-1) expression is associated with early plaque
progression and promotes macrophage survival. J Transl Med 2017;15:234. DOI PubMed PMC

161. Chandra D, Londino J, Alexander S, et al. The SCFFBXO3 ubiquitin E3 ligase regulates inflammation in atherosclerosis. J Mol Cell Cardiol 2019;126:50-9. DOI PubMed PMC

162. Di Gregoli K, Somerville M, Bianco R, et al. Galectin-3 identifies a subset of macrophages with a potential beneficial role in atherosclerosis. Arterioscler Thromb Vasc Biol 2020;40:1491-509. DOI PubMed PMC

163. Falcone C, Lucibello S, Mazzucchelli I, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905-13. DOI PubMed PMC

164. Varasteh Z, De Rose F, Mohanta S, et al. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using \(^{89}\text{Zr}\text{-DFo-Coca3}\text{-F(ab')\text{2}}\text{mAb. Theranostics 2021;11:1864-76. DOI PubMed PMC}

165. Karlsson A, Christenson K, Mattak M, et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009;19:16-20. DOI PubMed PMC

166. Erriah M, Pabreja K, Fricker M, et al. Galectin-3 enhances monocyte-derived macrophage effector cytokinesis of apoptotic granulocytes in asthma. Respir Res 2019;20:1. DOI PubMed PMC

167. Lepur A, Carlsson MC, Novak R, Dumić J, Nilsson UJ, Leffler H. Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta 2012;1820:804-18. DOI PubMed PMC

168. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-98. DOI PubMed PMC

169. Cassaglia P, Penas F, Betazza C, et al. Genetic deletion of galectin-3 alters the temporal evolution of macrophage infiltration and healing affecting the cardiac remodeling and function after myocardial infarction in mice. Am J Pathol 2020;190:1789-800. DOI PubMed PMC

170. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008;180:2650-8. DOI PubMed PMC

171. Shiraikawa K, Endo J, Kataoka M, et al. (Interleukin)-10-STAT3-Galectin-3 axis is essential for osteopontin-producing reparative macrophage polarization after myocardial infarction. Circulation 2018;138:2021-35. DOI PubMed PMC

172. Iacobini C, Menini S, Ricci C, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29:831-6. DOI PubMed PMC

173. Gleissner CA, Erbel C, Linden F, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis 2017;260:247-9. DOI PubMed PMC

174. Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galectin-3 is a potential mediator for atherosclerosis. J Immunol Res 2020;2020:5284728. DOI PubMed PMC

175. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015;12:10-7. DOI PubMed PMC

176. Lee SG, Oh J, Bong SK, et al. Macrophage polarization and acceleration of atherosclerotic plaques in a swine model. Am J Pathol 2019;190:1789-800. DOI PubMed PMC

177. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008;180:2650-8. DOI PubMed PMC

178. Kong M, Zhuo X, Ma A. STAT6 Upregulation promotes M2 macrophage polarization to suppress atherosclerosis. Basic Res Cardiol 2018;13:e0193005. DOI PubMed PMC

179. Gong M, Zhuo X, Ma A. STAT6 Upregulation promotes M2 macrophage polarization to suppress atherosclerosis. PLoS One 2018;13:e0193005. DOI PubMed PMC

180. Zheng Y, Li H, Zhang J, et al. Insulin inhibits inflammation and promotes atherosclerotic plaque stability via PI3K-Akt pathway activation. Immunol Lett 2016;170:7-14. DOI PubMed PMC

181. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol 2017;198:1006-14. DOI PubMed PMC

182. Linton MF, Moslehji JJ, Babaev VR. Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis. Int J Mol Sci 2019;20:2703. DOI PubMed PMC

183. Xu R, Li C, Wu Y, et al. Role of KCa3.1 Channels in macrophage polarization and its relevance in atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2017;37:226-36. DOI PubMed PMC

184. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Immunol 2011;12:750-1. DOI PubMed PMC

185. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-96. DOI PubMed PMC

186. Bosso P, Polentarutti N, Sironi M, et al. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002;99:3427-31. DOI PubMed PMC

187. Joffre J, Potteaux S, Zeboudj L, et al. Genetic and pharmacological inhibition of TREM-1 limits the development of experimental atherosclerosis. J Am Coll Cardiol 2016;68:2776-93. DOI PubMed PMC

188. Yurtseven E, Ural D, Baysal K, Tokgozoglu L. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb 2020;27:909-18. DOI PubMed PMC

189. Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kB pathway. Atherosclerosis 2017;262:113-22. DOI PubMed PMC

190. Song Y, BSH, Trigatti BL. Un-JAMming atherosclerotic arteries: JAM-L as a target to attenuate plaque development. Clin Sci (Lond) 2019;133:1581-5. DOI PubMed PMC

191. Yang C, Lu M, Chen W, et al. Thryotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques. J Exp Med
Liu et al. Vessel Plus 2021;5:43 | https://dx.doi.org/10.20517/2574-1209.2021.25
Ding S, Lin N, Sheng X, et al. Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner. *J Pineal Res* 2019;67:e12581. DOI PubMed

Qiao L, Zhang X, Liu M, et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by improving autophagy and lipid metabolism in macrophage foam cells. *Front Pharmacol* 2017;8:727. DOI PubMed PMC

Zhang X, Liu MH, Qiao L, et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype. *J Cell Mol Med* 2018;22:409-16. DOI PubMed PMC

Chen Z, Zhao R, Zhao Y, et al. Oleoylethanolamide stabilizes atherosclerotic plaque through regulating macrophage polarization via AMPK-PPARα pathway. *Biochem Biophys Res Commun* 2020;524:308-16. DOI PubMed

Guo M, Xiao J, Sheng X, et al. Ginsenoside Rg3 mitigates atherosclerosis progression in diabetic apoE−/− mice by skewing macrophages to the M2 phenotype. *Front Pharmacol* 2018;9:464. DOI

Chen F, Guo N, Cao G, Zhou J, Yuan Z. Molecular analysis of curcumin-induced polarization of murine RAW264.7 macrophages. *J Cardiovasc Pharmacol* 2014;63:544-52. DOI PubMed

Jacob A, Wu R, Zhou M, Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. *PPAR Res* 2007;2007:89369. DOI PubMed PMC

Meng Z, Yan C, Deng Q, Gao DF, Niu XL. Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways. *Acta Pharmacol Sin* 2013;34:901-11. DOI PubMed PMC

Zhou Y, Zhang T, Wang X, et al. Curcumin modulates macrophage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways. *Cell Physiol Biochem* 2015;36:631-41. DOI PubMed

Cao J, Han Z, Tian L, et al. Curcumin inhibits EMMPRIN and MMP-9 expression through AMPK-MAPK and PKC signaling in PMA induced macrophages. *J Transl Med* 2014;12:266. DOI PubMed PMC

Wang N, Zhang X, Ma Z, et al. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE−/− mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling. *Biomed Pharmacother* 2020;123:109729. DOI PubMed

Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. *Atherosclerosis* 2015;242:639-46. DOI PubMed

Skiba DS, Nosalski R, Mikolajczyk TP, et al. Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. *Br J Pharmacol* 2017;174:4055-69. DOI PubMed PMC

Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. *Fundam Clin Pharmacol* 2014;28:221-9. DOI PubMed

Brenner C, Franz WM, Kühlenthal S, et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. *Int J Cardiol* 2015;189:163-9. DOI PubMed

Shen L, Sun Z, Nie P, et al. Sulindac-derived retinoid X receptor-a modulator attenuates atherosclerotic plaque progression and destabilization in ApoE−/− mice. *Br J Pharmacol* 2019;176:2559-72. DOI

Singla DK, Johnson TA, Tavakoli Dargani Z. Exosome treatment enhances anti-inflammatory M2 Macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy. *Cells* 2019;8:1224. DOI PubMed PMC